In a welcome move, GSK ADR saw its Relative Strength Rating improve from 69 to 75 on Monday. Please watch the video at ...

NEW YORK CITY, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

GSK (LON:GSK – Get Free Report)‘s stock had its “underweight” rating reaffirmed by equities research analysts at JPMorgan ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...

Stock analysts at Zacks Research upped their FY2027 earnings per share estimates for GSK in a report issued on Tuesday, March ...

GSK PLC closed 18.56% short of its 52-week high of £18.24, which the company achieved on May 16th.

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.